Sign up USA
Proactive Investors - Run By Investors For Investors
EPIC: AGY
Market: AIM
Sector: Pharma & Biotech
Phone: +44 (0)1903 844 700
Address: Dominion Way, Worthing, West Sussex BN14 8SA.
Website: www.allergytherapeutics.com
Allergy Therapeutics plc

Allergy Therapeutics plc

We provide information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with a special focus on allergy vaccination (also known as specific immunotherapy or desensitisation therapy). Allergy vaccination is a successful treatment that deals with the underlying cause of allergies and not just the symptoms! Allergy Therapeutics has a long-term commitment to the development of innovative therapies for allergy treatment and allergy prevention.

Allergy Therapeutics plc

www.allergytherapeutics.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Allergy Therapeutics plc


Allergy Therapeutics plc Snapshot

Corporate Overview

Allergy Therapeutics® is a Europe-based specialty pharmaceutical company focused upon the diagnosis and treatment of allergy. Allergy Therapeutics has an existing sales base of approximately £40 million per annum, an MHRA-approved manufacturing capability, as well as an established sales and marketing infrastructure in several major European markets. In addition, the Company has a number of novel compounds which have already undergone initial clinical evaluation and, once registered, could potentially revolutionise the treatment of allergy.


Allergy Therapeutics offers:

  • An established range of diagnostics and specific immunotherapy vaccines.
  • Certain exclusive rights to MPL® - a novel immunological adjuvant in the field of allergy.
  • An innovative product development pipeline supported by documented clinical evidence of efficacy and safety.
  • Intellectual property rights to five patent families. Patent protection extending between 2018-24.
  • A highly qualified scientific and commercial team with industry experienced management.
  • A European sales and marketing team in Germany, Italy, Spain, UK, Netherlands and Austria, plus a distributor network in Canada, Eastern Europe and South Korea.
  • High-quality facilities that offer compliance with Current Good Manufacturing Practices (CGMP) and increased production capacity.

Mission

Our aim is to create a sustainable, fast-growing and profitable European pharmaceutical business with a substantial franchise in the allergy sector. We will achieve this by developing innovative, patented, registered aluminium-free therapies for both the treatment and prevention of allergy-related conditions.


Business, Commercial & Development Strategy

Allergy Therapeutics is a European pharmaceutical company. Its sales and much of its development effort are focused on the area of immunotherapy for allergy. Immunotherapy acts on the underlying immunological cause of the disease. It thereby provides continued treatment which addresses the symptoms of the disease. The right immunotherapeutic products should have great commercial potential.


Allergy Therapeutics' strategies are therefore to:

  • Continue to build our European commercial infrastructure.
  • Continue developing improved allergy vaccines with novel adjuvants, improved dosing characteristics, patient compliance and new delivery formulations that result in a patent protected, registered product.
  • Broaden the portfolio through the in-licensing and co-development of selected products.
  • Develop the aluminium-free vaccines.
  • Identify strong commercial partners for non-European specialist markets.
  • To develop opportunities with allergy vaccines in the US market.

Our Products

Pollinex® Trees

Composition

Pollinex® Trees contains glutaraldehyde-modified, standardised allergen extracts (allergoids) of 3 common tree pollens: (Alder (Alnus spp.), Birch (Betula spp.) and Hazel (Corylus spp.)) adsorbed onto L-tyrosine. Other ingredients contained in Pollinex® Trees include: L-tyrosine, phenol, glycerol, sodium chloride, buffer salts and water for injections.


Indications

Pollinex® Trees is indicated for treatment of seasonal allergic hayfever due to tree pollen in patients who have failed to respond adequately to anti-allergy drugs. Careful consideration of the patient's history and diagnosis with a positive skin prick test and/or IgE test need to be conducted prior to treatment.

Method of Administration

Pollinex® Trees is formulated as a subcutaneous injection.

Presentation

Pollinex® Trees is presented in vials. The packs available are as follows:
Initial Course: 3 vials (No. 1 – No. 3) containing graduated doses (300 standardised units (SU)/0.5 ml (No. 1), 800 SU/0.5 ml (No. 2) and 2,000 SU/0.5 ml (No. 3))
Extension Course: 1 vial of the No. 3 strength (2,000 SU/0.5 ml)
Click here for the UK Summary of Product Characteristics (SPC)
Click here for the Extension Course UK Summary of Product Characteristics (SPC)

 

Pollinex® Grasses + Rye

Pollinex Grasses and Rye Allergy Therapeutics

Composition


Pollinex® Grasses + Rye contains glutaraldehyde-modified, standardised allergen extracts (allergoids) of the following 13 common grass pollens adsorbed onto L-tyrosine:
Foxtail (Alopecurus pratensis), Crested Dogstail (Cynosurus cristatus), Cocksfoot (Dactylis glomerata), Rye grass (Lolium perenne), Meadow grass (Poa pratensis), Vernal (Anthoxanthum odoratum), Fescue (Festuca pratensis), Bent (Agrostis tenuis), Timothy (Phleum pratense), Brome (Bromus spp.), Oat grass (Arrhenatherum elatius),Yorkshire Fog (Holcus lanatus), Cultivated Rye (Secale cereale).

Other ingredients contained in Pollinex® Grasses + Rye include: L-tyrosine, phenol, glycerol, sodium chloride, buffer salts and water for injections.

Indications


Pollinex® Grasses + Rye is indicated for treatment of seasonal allergic hayfever due to grass pollen in patients who have failed to respond adequately to anti-allergy drugs. Careful consideration of the patient's history and diagnosis with a positive skin prick test and/or IgE test need to be conducted prior to treatment.

Method of Administration 


Pollinex® Grasses + Rye is formulated as a subcutaneous injection.

Presentation 


Pollinex® Grasses + Rye is presented in vials. It is available in packs containing both the following courses:

Initial Course: 3 vials (No. 1 – No. 3) containing graduated doses (300 standardised units (SU)/0.5 ml (No. 1), 800 SU/0.5 ml (No. 2) and 2,000 SU/0.5 ml (No. 3))
Extension Course: 1 vial of the No. 3 strength (2,000 SU/0.5 ml)
Click here for the UK Summary of Product Characteristics (SPC)
Click here for the Extension Course UK Summary of Product Characteristics (SPC)

 

Skin Prick Testing

This is the primary mode of testing for immediate IgE-mediated allergy. It is widely practised and can provide high-quality information when performed optimally and interpreted correctly.

Small amounts of allergen are introduced into the epidermis and interact with specific IgE bound to cutaneous mast cells. Histamine and other mediators are released, leading to a visible “wheal-and-flare” reaction peaking after about 15 minutes. Skin prick testing should be used to confirm the diagnosis of allergy when added to the history and clinical examination. It differentiates allergic diseases from other mimicking conditions. It may lead to allergen avoidance strategies, improved use of medications, and for some patients, Immunotherapy.

“Skin prick testing is usually the first test recommended when an allergy is suspected. The advantages are that it is a simple, quick (providing results within 15-20 minutes) and inexpensive form of testing.”

Allergy UK

The UK guideline “Good Allergy Practice” contains the following statement:


“A diagnosis of allergy is based first and foremost on a careful clinical history.
Skin tests should be used to support (or otherwise) a diagnosis of allergy. The skin prick test is the method of choice for the diagnosis of immediate-type hypersensitivity.”

 

To view Diagnostic Products please click here

Maunel Llobet
Chief Executive Officer

Manuel joined the Group in July 2009 following the successful refinancing in which Azure Ventures Limited was the main investor. As Chief Executive Officer, Manuel is responsible for the executive management of group operations, investor relations, and implementation of the Board’s collective decisions overseeing all operational aspects of the Group and directing the long-term strategy.
Please refer to The Board for further information.



Ian Postlethwaite
Finance Director and Company Secretary

Ian joined Allergy Therapeutics in April 2002 as Finance Director. 
As Finance Director, Ian is responsible for group financial reporting and control, tax, finance systems and internal audit. He is also the Company Secretary - a position he has held since 2004.
Please refer to The Board for further information.

Tim Higenbottam
Research & Development Director

Tim is a recognised expert in Respiratory Medicine including asthma and has extensive experience in clinical development and regulatory affairs from within the pharmaceutical industry and academia. Tim was Professor of Medicine at Sheffield University between 1995 and 2001 and from 2001, he held senior positions with AstraZeneca before moving onto Chiesi Farmaceutici as a Corporate Director. He joins Allergy Therapeutics from TranScrip Partners where he was a Senior Partner.



Santiago Puig
Business Development Director

Santiago Puig joined Allergy Therapeutics in September 2009. Prior to this he worked for Alliance Boots as Director of International Trading based in Spain. Previously Santiago has worked for Mepha AG/ Merckle-Ratiopharm Group in Switzerland and Laboratorios Andromaco in Chile.
Santiago started his career at the Deutsche Bank working in corporate finance in Germany and Spain. He has an MBA from IESE, Universidad de Navarra, Barcelona and a degree in economics. As Business Development Director, Santiago is responsible for growing the business through market expansion, M&A, joint ventures and licensing deals.



Prof. Dr. Matthias Kramer
International Medical Director

Matthias Kramer is the International Medical Director of Allergy Therapeutics. He is a medical doctor with outstanding experience in allergy and has also worked at the University of Munich in the Department of Oto-Rhino-Laryngology, Head and Neck Surgery as the Managing Senior Consultant and Head of the Allergy Division. He was also a member of the Executive Board of the university’s “Interdisciplinary Center of Allergy” before moving to Allergy Therapeutics in May 2013.



Nunzio Di Grazia
Regional Director, Italy & Spain

Nunzio started in 2008 as General Manager of Allergy Therapeutics Italian subsidiary and in 2011 was appointed General Manager of Spain and other territories. He has over 25 years’ experience working in the pharmaceutical industry, primarily in Italy, and then in Southern Europe and Latin America.
Prior to this he has worked for Organon, Menarini, for Abbott and for Enteral Nutrition Division. Nunzio has a degree in chemistry and a degree in pharmacy, plus a masters degree in finance and key account management.



Bodo Steinert
Regional Director, Germany & Austria

After studying biology, Bodo Steinert started his career in 1988 at Beecham Wülfing in the allergy department of Bencard.
He worked as a Trainer, Sales Representative and Project Manager. In 1992, he left Beecham to join HAL Allergie, and finally was made Corporate Marketing Manager with responsibility for the whole HAL group. In 2002, he returned to Bencard Allergie as Sales Manager. In 2005 he founded the Austrian subsidiary of Bencard and he is the Managing Director of Germany & Austria. Bodo has substantial experience in the German and Austrian allergology markets, has launched many products in his career and is an expert in implementing marketing & sales concepts.



Bev Lees
Operations Director

Bev joined Allergy Therapeutics in 1998 and has extensive experience in Quality Systems. Prior to joining Allergy Therapeutics, she held positions in Quality Assurance and Quality Control within Smithkline Beecham and worked as a Haematologist/ Serologist MLSO in the NHS. In addition Bev has extensive regulatory experience chairing meetings with regulatory agencies in UK, Japan, U.S, Canada and European agencies.
She has authored a variety of scientific posters, spoken at allergy congresses and chaired a session on Quality Systems, Pharmaceutical Development and Validation



Dr. Murray Skinner
Chief Scientific Officer

Murray Skinner joined Allergy Therapeutics in 2004 having previously held positions within quality, scientific and regulatory settings of the pharmaceutical industry including Serologicals, Millipore and Patheon. He has experience in the global market supply of a diverse range of pharmaceutical products including biologics and NCE’s and understands the specific regulations that under-pin product licensure and supply.
Murray completed his PhD with the Medical Research Council and University of London following which he was a visiting lecturer and research fellow at Imperial College. He has also published a number of patents and scientific articles in the field of allergy and vaccine development.

 

 

Allergy Therapeutics,
Dominion Way, 

Worthing,
West Sussex, 

BN14 8SA,
United Kingdom

Nomad and Broker: Panmure Gordon (UK) Limited
Panmure Gordon & Co
One New Change
London
EC4M 9AF
UK


Bank: Royal Bank of Scotland PLC
21 Broad Street
Hereford
HR4 9AP


Auditor: Grant Thornton UK LLP
Grant Thornton House
Melton Street
Euston Square
London
NW1 2EP


Financial PR: FTI Consulting
1101 K Street NW
Suite B100
Washington, DC 20005


United States


Solicitors: Covington & Burling LLP & Cotley LLP
265 Strand
London
WC2R 1BH

Allergy Therapeutics plc Timeline

Market Reports Including AGY

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC